Parham Mokri, MD
Nephrology · Bakersfield, CANPI 1720036692
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,031 of the $5,112 with a category attached, or 78.9%. It is spread thinly across 22 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,377 and has fallen 99.3% since, to $17 in 2025.
Across 208 payments — averaging $24.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Baxter Healthcare$862
- Amgen$765
- AstraZeneca$736
- Daiichi Sankyo Inc.$414
- Vifor Pharma, Inc.$407
- Bayer$334
- plus $2K from 16 others
Across 686 payments — averaging $836.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$570K
- AstraZeneca$4K
What the payments were for
- Consulting fees$86217%
- Speaking & faculty fees$2004%
- Food & beverage$4,03179%
- Education$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Baxter Healthcare | 1 | $862 |
| Amgen(2 entities) | 32 | $765 |
| AstraZeneca(2 entities) | 38 | $736 |
| Daiichi Sankyo Inc. | 19 | $414 |
| Vifor Pharma, Inc. | 13 | $407 |
| Bayer | 19 | $334 |
| Fresenius USA Marketing, Inc. | 23 | $310 |
| GSK | 14 | $232 |
| Akebia Therapeutics Inc | 12 | $231 |
| Otsuka America Pharmaceutical, Inc. | 12 | $221 |
| Aurinia Pharma U.S., Inc. | 8 | $174 |
| Sanofi | 2 | $122 |
| OPKO Pharmaceuticals, LLC | 4 | $84 |
| Ultragenyx Pharmaceutical Inc. | 2 | $46 |
| Alnylam Pharmaceuticals Inc. | 2 | $41 |
| Travere Therapeutics, Inc. | 1 | $25 |
| Mallinckrodt Hospital Products Inc. | 1 | $24 |
| Mallinckrodt Enterprises LLC | 1 | $22 |
| Novartis | 1 | $22 |
| Genentech USA, Inc. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Xeris Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Renal - Revaclear$862
- Veltassa$200
- FABRAZYME$102
How this compares
$5,112 in reported general payments places this provider in the 80th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 129 | $445,428 |
| Sevelamer Carbonate | 293 | $67,953 |
| XphozahTenapanor Hcl | 19 | $55,855 |
| LokelmaSodium Zirconium Cyclosilicate | 44 | $39,841 |
| Cinacalcet Hcl | 98 | $37,075 |
| RenvelaSevelamer Carbonate | 12 | $31,515 |
| VeltassaPatiromer Calcium Sorbitex | 36 | $31,463 |
| Ondansetron Hcl | 72 | $26,386 |
| KerendiaFinerenone | 25 | $20,834 |
| Calcium Acetate | 268 | $17,421 |
| ProcritEpoetin Alfa | 11 | $14,598 |
| FarxigaDapagliflozin Propanediol | 17 | $14,195 |
| Clonidine | 78 | $10,992 |
| Tacrolimus | 87 | $9,830 |
| Mycophenolic AcidMycophenolate Sodium | 16 | $5,824 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $310 | $445,428129 claims |
| AstraZenecaLokelma, Farxiga | $736 | $54,03661 claims |
| BayerKerendia | $334 | $20,83425 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,341 nephrology providers in California.
Other nephrology in Bakersfield
- Hashim KazmiBakersfield$99K
- Anjay RastogiLos Angeles$2.2M
- Glenn ChertowStanford$2M
- Luis AlvarezPalo Alto$1.8M
- Jose MorfinSacramento$1M
- Rodolfo BatarseRancho Mirage$910K
- Vandana MathurWoodside$769K
- Yasir QaziOrange$618K
- Rafael VillicanaLoma Linda$610K
- Sunil PatelApple Valley$509K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.